A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma

Trial Profile

A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Remetinostat (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Therapeutic Use
  • Sponsors TetraLogic Pharmaceuticals
  • Most Recent Events

    • 13 Oct 2017 According to a Medivir AB media release, data were presented as an abstract at the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force meeting October 2017.
    • 13 Oct 2017 Results presented in a Medivir AB media release.
    • 07 Apr 2017 According to a Medivir AB media release, company is planning present full data at scientific meetings in the second half of 2017. Based on the data from this trial company is planning to initiate discussions with regulatory authorities with the aim of initiating a phase III study (see profile 278464) later in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top